There are 2789 resources available
1052P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: ePoster Display
1014P - Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma
Presenter: April Salama
Session: ePoster Display
1015P - A phase I dose-escalation study of HBM4003: An anti-CTLA-4 heavy-chain-only mAb
Presenter: Paul de Souza
Session: ePoster Display
1016P - ImmTAC redirect exhausted tumor-infiltrating T-cells: An effect enhanced by pembrolizumab against PD-L1+ tumors
Presenter: Kristina Petrovic
Session: ePoster Display
1056P - Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study
Presenter: Ivan Marquez-Rodas
Session: ePoster Display
1057P - ROS1 mutation can serve- as a potential efficacious predictor of immunotherapy in melanoma patients
Presenter: Hucheng Liu
Session: ePoster Display
1058P - Treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients (pts) with checkpoint inhibition–refractory advanced cutaneous melanoma
Presenter: Manon Pillai
Session: ePoster Display
1021P - Long non-coding RNAs influence cancer immunotherapy efficacy through regulating T-cell infiltration and activity or tumor antigenicity
Presenter: Anlin Li
Session: ePoster Display
1060P - Serum metabolomic profiling reveals differences in polyamine and tryptophan metabolites in patients with cutaneous, mucosal and uveal melanoma
Presenter: Maysa Vilbert
Session: ePoster Display
1061P - Safety of cemiplimab for advanced cutaneous squamous cell carcinoma: The Spanish named patient programme
Presenter: Almudena Garcia Castano
Session: ePoster Display
Resources:
Abstract